del Carmen Alamo, MaOchenduszko, SebastianCrespo, GuillermoCorral, MonicaOramas, JuanaSancho, PilarMedina, JavierGaricano, FernandoLopez, PedroCampos Balea, BegonaRodriguez Garzotto, AnaliaMunoz-Couselo, Eva2025-01-072025-01-072021-01-011178-6930https://hdl.handle.net/10668/26599Background: The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness of the combination therapy with vemurafenib/cobimetinib in terms of durability, and to describe differential characteristics in patients associated to durable responses in real-world settings.Patients and Methods: Retrospective, observational, cross-sectional, multicenter study involving 41 patients with advanced melanoma harboring a BRAF(v600) mutation who initiated a combination therapy with vemurafenib/cobimetinib between May 2018 and March 2019. Participants were differentiated regarding the durability of the response: durable (complete response, CR, or a partial response, PR, for at least 12 months) and non-durable (stable disease, SD, progressive disease, PD, or CR/PRenAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/vemurafenibcobimetinibBRAFmetastatic melanomadurable responseclinical practiceCombinationMortalityOutcomesTherapyCohortV600eresearch article34866914open access10.2147/OTT.S325208https://www.dovepress.com/getfile.php?fileID=76226723709200002